| Literature DB >> 34445487 |
Yaping Wang1, Jian Shi2, Xiaoyong Tong1.
Abstract
Mechanosensitive ion channels are widely expressed in the cardiovascular system. They translate mechanical forces including shear stress and stretch into biological signals. The most prominent biological signal through which the cardiovascular physiological activity is initiated or maintained are intracellular calcium ions (Ca2+). Growing evidence show that the Ca2+ entry mediated by mechanosensitive ion channels is also precisely regulated by a variety of key proteins which are distributed in the cell membrane or endoplasmic reticulum. Recent studies have revealed that mechanosensitive ion channels can even physically interact with Ca2+ regulatory proteins and these interactions have wide implications for physiology and pathophysiology. Therefore, this paper reviews the cross-talk between mechanosensitive ion channels and some key Ca2+ regulatory proteins in the maintenance of calcium homeostasis and its relevance to cardiovascular health and disease.Entities:
Keywords: Ca2+; IP3R; NCX; Orai; Piezo channels; SERCA; STIM; TRP channels; cardiovascular disease; mechanosensitive ion channels
Mesh:
Substances:
Year: 2021 PMID: 34445487 PMCID: PMC8395829 DOI: 10.3390/ijms22168782
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Ca2+ links Ca2+ regulatory proteins with mechanosensitive ion channels to regulate cardiovascular health and diseases. The mechanical stress generated in either cardiovascular health or disease directly stimulates mechanosensitive ion channels and induces Ca2+ entry. Then the Ca2+ regulatory proteins sensing the changes of Ca2+ cross-talk to or interact with mechanosensitive ion channels, which contributes to the development of cardiovascular disease or health.
Current clinical trials for drugs targeting these Ca2+ regulatory proteins in the cardiovascular system according to the ClinicalTrials.gov website (available online and accessed on 12 August 2021).
| Ca2+ Regulatory Proteins | Treatment | Cardiovascular Disease | Phase |
|---|---|---|---|
| SERCA | AAV1/SERCA2a (MYDICAR) [ | Ischemic cardiomyopathy; non-ischemic cardiomyopathy; heart failure; cardiomyopathies | Phase 2 |
| MYDICAR-single intracoronary infusion [ | Heart failure, congestive; ischemic cardiomyopathy; non-ischemic cardiomyopathy | Phase 2 | |
| MYDICAR [ | Chronic heart failure | Phase 2 | |
| SRD-001 [ | Congestive and systolic heart failure | Phase 1/Phase 2 | |
| Istaroxime [ | Heart failure [ | Early phase 1 | |
| NCX | MYDICAR [ | Chronic heart failure | Phase 2 |
| Orai | No resource | No resource | No resource |
| STIM | No resource | No resource | No resource |
| IP3R | No resource | No resource | No resource |
Current clinical trials for drug specifically targeting these mechanosensitive ion channels are run in the cardiovascular system, according to the ClinicalTrials.gov website (available online and accessed on 12 August 2021).
| Mechanosensitive Ion Channels | Treatment | Cardiovascular Disease | Phase |
|---|---|---|---|
| Piezo | Senicapoc (synonyms: ICA-17043; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide) [ | Dehydrated hereditary stomatocytosis (related to pulmonary hypertension [ | Phase 1/Phase 2 |
| TRPV1 | Capsaicin and mechanical stimulation with Von Frey filaments [ | Cystinosis (related to portal hypertension [ | Early phase 1 |
| TRPV4 | GSK2798745 [ | Heart failure | Phase 2 |
| TRPM8 | Menthol [ | Hypertension [ | Phase 2/Phase 3 |
Summary of the cross-talk between mechanosensitive ion channels and Ca2+ regulatory proteins in cardiovascular health and disease.
| Mechanosensitive Ion Channels | Ca2+ Regulatory Proteins | Cardiovascular Health | Cardiovascular Disease |
|---|---|---|---|
| Piezo | SERCA | Inhibition of piezo-dependent endothelial cell migration [ | No resource |
| TRP | NCX | Cell contraction, proliferation and migration [ | Pulmonary hypertension [ |
| Orai | Participation in SOCE [ | Pulmonary hypertension [ | |
| STIM | SOCE activation [ | Hypertension and atherosclerosis [ | |
| IP3R | Vasoconstriction; regulating the VGCC function [ | Hypertension [ | |
| SERCA | Heartbeat and heart development [ | Cardiac hypertrophy [ |